EfficacyHigh
Studies8
Participants6,200
StatusAvailable
Retatrutide
LY3437943
Retatrutide is a novel triple hormone receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors for superior metabolic effects. This innovative approach produces enhanced appetite suppression, improved insulin sensitivity, and increased energy expenditure, potentially delivering 20-25% weight loss in clinical trials.
Clinical Safety Profile
Reported Side Effects
Nausea (most common, usually transient)
Vomiting
Diarrhea
Constipation
Abdominal pain
Injection site reactions
Fatigue during dose escalation
Decreased appetite
Headache
Dizziness
Side Effect Management (Clinical Trial Data)
Nausea
Common
42.1%
Vomiting
Common
24.7%
Diarrhea
Common
23.8%
Constipation
Common
19.3%
Abdominal Pain
Common
18.5%
Injection Site Reactions
Occasional
12.4%
Side Effect Management Strategies
Nausea: Take with food, smaller meals, ginger supplements
Vomiting: Slower dose escalation, anti-emetics if severe
Diarrhea: Adequate hydration, probiotics, bland diet
Constipation: Increase fiber intake, adequate fluids, light exercise
Clinical Safety Metrics
Variable
Overall Safety Rating
Variable
Discontinuation Rate
Research
Approved Status
CONTRAINDICATIONS
• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Severe gastroparesis
• Diabetic ketoacidosis
Medical Disclaimer
Retatrutide is currently in Phase 3 clinical trials and is not yet FDA approved. This information is for educational purposes only and should not replace medical advice. Consult with healthcare providers familiar with investigational therapies for personalized guidance. Side effects and contraindications are based on available clinical trial data.